Clinical Trial Update: Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial update for a bicistronic CAR-T cell therapy targeting CD19 and CD20 in B-cell malignancies; current status is not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Chronic Lymphocytic Leukemia

Drugs mentioned

• Anti-CD19/Anti-CD20 bicistronic CAR-T cells

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING